Escitalopram structure
|
Common Name | Escitalopram | ||
---|---|---|---|---|
CAS Number | 128196-01-0 | Molecular Weight | 324.39 | |
Density | 1.2±0.1 g/cm3 | Boiling Point | 428.3±45.0 °C at 760 mmHg | |
Molecular Formula | C20H21FN2O | Melting Point | N/A | |
MSDS | N/A | Flash Point | 212.8±28.7 °C |
Use of EscitalopramEscitalopram is a selective serotonin reuptake inhibitor (SSRI) with Ki of 0.89 nM.Target: SSRIsEscitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Escitalopram may be used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD). Escitalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of escitalopram is found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Escitalopram does not inhibit monoamine oxidase. |
Name | escitalopram |
---|---|
Synonym | More Synonyms |
Description | Escitalopram is a selective serotonin reuptake inhibitor (SSRI) with Ki of 0.89 nM.Target: SSRIsEscitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Escitalopram may be used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD). Escitalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of escitalopram is found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Escitalopram does not inhibit monoamine oxidase. |
---|---|
Related Catalog | |
Target |
Human Endogenous Metabolite |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 428.3±45.0 °C at 760 mmHg |
Molecular Formula | C20H21FN2O |
Molecular Weight | 324.39 |
Flash Point | 212.8±28.7 °C |
PSA | 110.86000 |
LogP | 2.51 |
Vapour Pressure | 0.0±1.0 mmHg at 25°C |
Index of Refraction | 1.591 |
Storage condition | 2-8℃ |
HS Code | 2932999099 |
---|
Precursor 9 | |
---|---|
DownStream 4 | |
HS Code | 2932999099 |
---|---|
Summary | 2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
MFCD06407826 |
UNII-4O4S742ANY |
Escitalopram |
5-Isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, (1S)- |
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile |
Seroplex |
Citalopram |
(+)-Citalopram |
Lexapro |
(S)-citalopram |
S(+)-citalopram |
Cipralex |
S-(+)-Citalopram |
(1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile |